Neurochemical changes in a double transgenic mouse model of Alzheimer's disease fed a pro-oxidant diet

Neurochemistry International

Volumn 57, Issue 5, 2010, Pages 504-511

  Ash, Elizabeth S ^a   Alavijeh, Mohammad S ^a   Palmer, Alan M ^a   Mitchelmore, Cathy ^b   Howlett, David R ^c   Francis, Paul T ^c   Broadstock, Martin ^c   Richardson, Jill C ^d  

^a Pharmidex   (United Kingdom)

^b ROSKILDE UNIVERSITY   (Denmark)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Alzheimer's disease; Monoamines; Pro oxidant diet; TASTPM mice; Tyrosine hydroxylase

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; NORADRENALIN; SEROTONIN; TYROSINE 3 MONOOXYGENASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DIET; ELECTROCHEMICAL DETECTION; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; MALE; MOUSE; NEOCORTEX; NERVE FIBER DEGENERATION; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PRO OXIDANT DIET; TRANSGENIC MOUSE; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BIOGENIC MONOAMINES; BLOTTING, WESTERN; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIET; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROTRANSMITTER AGENTS; OXIDANTS; OXIDATIVE STRESS; PRESENILINS; REFERENCE STANDARDS; TRANSGENES; TYROSINE 3-MONOOXYGENASE;

MUS; MUS MUSCULUS;

EID: 77956226666     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.06.013     Document Type: Article

References (50)

1. Abdul H.M., Sultana R., St.Clair D.K., Markesbery W.R., Butterfield D.A. Oxidative damage in brain from human mutant APP/PS-1 double knock-in mice as a function of age. Free Radic. Biol. Med. 2008, 45:1420-1425.
2. Ambrée O., Richter H., Sachser N., Lewejohann L., Dere E., de Souza Silva M.A., Herring A., Keyvani K., Paulus W., Schäbitz W.R. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease. Neurobiol. Aging 2009, 30:1192-1204.
3. Arai H., Kosaka K., Iizuka R. Changes of biogenic amines and their metabolites in post-mortem brains from patients with Alzheimer-type dementia. J. Neurochem. 1984, 43:388-393.
4. Bendlin B.B., Carlsson C.M., Gleason C.E., Johnson S.C., Sodhi A., Gallagher C.L., Puglielli L., Engelman C.D., Ries M.L., Xu G., Wharton W., Asthana S. Midlife predictors of Alzheimer's disease. Maturitas 2010, 65:131-137.
5. Burke W.J., Li S.W., Chung H.D., Ruggiero D.A., Kristal B.S., Johnson E.M., Lampe P., Kumar V.B., Franko M., Williams E.A., Zahm D.S. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 2004, 25:101-115.
6. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., Rostaing P., Triller A., Salem N., Ashe K.H., Frautschy S.A., Cole G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43:633-645.
7. Cao X., Wei Z., Gabriel G.G., Li X., Mousseau D.D. Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology. BMC Neurosci. 2007, 8:73.
8. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
9. Cross A.J., Crow T.J., Johnson J.A., Joseph M.H., Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Monoamine metabolism in senile dementia of the Alzheimer type. J. Neurol. Sci. 1983, 60:383-392.
10. Dutescu R.M., Li Q.X., Crowston J., Masters C.L., Baird P.N., Culvenor J.G. Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247:1213-1221.
11. Ebinger G., Bruyland M., Martin J.J., Herregodts P., Cras P., Michotte Y., Gommé L. Distribution of biogenic amines and their catabolites in brains from patients with Alzheimer's disease. J. Neurol. Sci. 1987, 77:267-283.
12. Francis P.T., Palmer A.M., Sims N.R., Bowen D.M., Davison A.N., Esiri M.M., Neary D., Snowden J.S., Wilcock G.K. Neurochemical studies of early-onset Alzheimer's disease. Possible influences on treatment. N. Engl. J. Med. 1985, 313:7-11.
13. Francis P.T., Ramírez M.J., Lai M.K. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 2010, 10.1016/j.neuropharm.2010.02.010.
14. Hartman R.E., Shah A., Fagan A.M., Schwetye K.E., Parsadanian M., Schulman R.N., Finn M.B., Holtzman D.M. Pomegranate juice decreases amyloid load and improves behaviour in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2006, 24:506-515.
15. Hellström-Lindahl E., Viitanen M., Marutle A. Comparison of Aβ levels in the brain of familial and sporadic Alzheimer's disease. Neurochem. Int. 2009, 55:243-252.
16. Hirata-Fukae C., Li H.F., Hoe H.S., Gray A.J., Minami S.S., Hamada K., Niikura T., Hua F., Tsukagoshi-Nagai H., Horikoshi-Sakuraba Y., Mughal M., Rebeck G.W., LaFerla F.M., Mattson M.P., Iwata N., Saido T.C., Klein W.L., Duff K.E., Aisen P.S., Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008, 1216:92-103.
17. Hooijmans C.R., Rutters F., Dederen P.J., Gambarota G., Veltien A., van Groen T., Broersen L.M., Lütjohann D., Heerschap A., Tanila H., Kiliaan A.J. Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docohexaenoic acid (DHA) diet or cholesterol enriched typical Western diet (TWD). Neurobiol. Dis. 2007, 28:16-29.
18. Howlett D.R., Richardson J.C., Austin A., Parsons A.A., Bate S.T., Davies D.C., Gonzalez M.I. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 2004, 1017:130-136.
19. Howlett D.R., Richardson J.C. The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP?. Histol. Histopathol. 2009, 24:83-100.
20. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
21. Hy L.X., Keller D.M. Prevalence of AD among whites: a summary by levels of severity. Neurology 2000, 55:198-204.
22. Imam S.Z., Ali S.F. Aging increases the susceptibility to methamphetamine-induced neurotoxicity in rats: correlation with peroxynitrite production and hyperthermia. J. Neurochem. 2001, 78:952-959.
23. Karuppagounder S.S., Pinto J.T., Xu H., Chen H.-L., Beal M.F., Gibson G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 2009, 54:111-118.
24. Kurt M.A., Davies D.C., Kidd M., Duff K., Rolph S.C., Jennings K.H., Howlett D.R. Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp. Neurol. 2001, 171:59-71.
25. Lanari A., Amenta F., Silvestrelli G., Tomassoni D., Parnetti L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech. Ageing Dev. 2006, 127:158-165.
26. Larner A.J., Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J. Neurol. 2006, 253:139-158.
27. Lau J.C., Lerch J.P., Sled J.G., Henkelman R.M., Evans A.C., Bedell B.J. Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer's disease. Neuroimage 2008, 42:19-27.
28. Lee H-g., Casadesus G., Zhu X., Castellani R.J., McShea A., Perry G., Peterson R.B., Bajic V., Smith M.A. Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem. Int. 2009, 54:84-88.
29. Magaki S., Raghavan R., Mueller C., Oberg K.C., Vinters H.V., Kirsch W.M. Iron, copper and iron regulatory protein 2 in Alzheimer's disease and related dementias. Neurosci. Lett. 2007, 418:72-76.
30. Manaye K.F., Wang P.C., O'Neill J.N., Huang S.Y., Xu T., Lei D.-L., Tizabi Y., Ottinger M.A., Ingram D.K., Mouton P.R. Neuropathological quantification of dtg APP/PS1: neuroimaging, stereology and biochemistry. Age (Dordrecht) 2007, 29:87-96.
31. Marlett M.W., Lucassen P.J., Perry G., Smith M.A., Zhu X. Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J. Alzheimers Dis. 2008, 15:199-210.
32. Meltzer C.C., Smith G., DeKosky S.T., Pollock B.G., Mathis C.A., Moore R.Y., Kupfer D.J., Reynolds C.F. Serotonin in aging, late-life depression, and Alzheimer's disease - the emerging role of functional imaging. Neuropsychopharmacology 1998, 18:407-430.
33. Mouton P.R., Chachich M.E., Quigley C., Spangler E., Ingram D.K. Caloric restriction attenuates amyloid deposition in middle-aged dtg APP/PS-1 mice. Neurosci. Lett. 2009, 464:184-187.
34. Nagatsu T., Iizuka R. Tyrosine hydroxylase, tryptophan hydroxylase, and the biopterin cofactor in the brains from patients with Alzheimer's disease. J. Neural Transm. 1989, 1:21.
35. Nazarali A.J., Reynolds G.P. Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a post-mortem study. Cell Mol. Neurobiol. 1992, 12:581-587.
36. Onogi H., Ishigaki S., Nakagawasai O., Arai-Kato Y., Arai Y., Watanabe H., Miyamoto A., Tan-no K., Tadano T. Influence of memantine on brain monoaminergic neurotransmission parameters in mice: neurochemical and behavioural study. Biol. Pharm. Bull. 2009, 32:850-855.
37. Patel B.A., Arundell M., Parker K.H., Yeoman M.S., O'Hare D. Simple and rapid determination of serotonin and catecholamines in biological tissue using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B 2005, 818:269-276.
38. Perez S.E., Lazarov O., Koprich J.B., Chen E.-Y., Rodriquez-Menendez V., Lipton J.W., Sisodia S.S., Mufson E.J. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1ΔE9 transgenic mice. J. Neurosci. 2005, 25:10220-10229.
39. Pugh P.L., Vidgeon-Hart M.P., Ashmeade T., Culbert A.A., Seymour Z., Perren M.J., Joyce F., Bate S.T., Babin A., Virley D.J., Richardson J.C., Upton N., Sunter D. Repeated administration of the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. J. Neuroinflamm. 2007, 4:8-24.
40. Qin W., Yang T., Ho L., Zhao Z., Wang J., Chen L., Zhao W., Thiyagarajan M., MacGrogan D., Rodgers J.T., Puigserver P., Sadoshima J., Deng H., Pedrini S., Gandy S., Sauve A.A., Pasinetti G.M. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 2006, 281:21745-21754.
41. Richardson J.C., Kendal C.E., Anderson R., Priest F., Gower E., Soden P., Gray R., Topps S., Howlett D.R., Lavender D.N., Clarke N.J., Barnes J.C., Haworth R., Stewart M.G., Rupniak H.T.R. Ultrastructural and behavioural changes precede changes in amyloid deposition in a transgenic model of Alzheimer's disease. Neuroscience 2003, 122:213-228.
42. Scarmeas N., Luchsinger J.A., Mayeux R., Stern Y. The Mediterranean diet and Alzheimer disease mortality. Neurology 2007, 69:1084-1093.
43. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
44. Selkoe D.J. Alzheimer's disease: genotypes, phenotypes and treatments. Science 1997, 275:630-631.
45. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 2002, 346:476-483.
46. Storga D., Vrecko K., Birkmayer J.G., Reibnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brain of Alzheimer patients. Neurosci. Lett. 1996, 203:29-32.
47. Studzinski C.M., Li F., Bruce-Keller A.J., Fernandez-Kim S.O., Zhang L., Weidner A.M., Markesbery W.R., Murphy M.P., Keller J.N. Effects of short-term Western diet on cerebral oxidative stress and diabetes related factors in APP×PS-1 knock-in mice. J. Neurochem. 2009, 108:860-866.
48. Szapacs M.E., Numis A.L., Andrews A.M. Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. Neurobiol. Dis. 2004, 16:572-580.
49. Van Dam D., Marescau B., Engelborghs S., Cremers T., Mulder J., Staufenbiel M., De Deyn P.P. Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochem. Int. 2005, 46:409-422.
50. Wolfe M.S. The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 2006, 45:7931-7939.